MedTrace Logo

Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant

NCT04104438 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2025-12-16

Study results available
· View outcomes & findings →

Summary

This is a study to help understand how well new combinations of immunosuppressive medications (medications that weaken your immune system to prevent your body from rejecting the transplanted liver) work compared to standard immunosuppressive medications after your liver transplant. Also the study will assess how safe the new combination of immunosuppressive medicines are and if there are any changes in how your kidneys work after taking these medicines.

Conditions

  • Asses Immunosuppression Modulation on Renal Recovery Post LT

Interventions

DRUG

Basiliximab 20 MG

Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30

Sponsors & Collaborators

  • Fady M Kaldas, M.D., F.A.C.S.

    lead OTHER

Principal Investigators

  • Fady M Kaldas, MD · UCLA Dept Surgery

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2024-09-30
Completion
2024-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04104438 on ClinicalTrials.gov